Evopoint Biosciences Inc. clinical trials
Also known as Sinovent.
The registry lists 21 studies whose lead sponsor is Evopoint Biosciences Inc.. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 21studies on the registry
- 12open to participants now
- 3phase 3 studies under way
- 5reach primary completion within a year
Get an email when these change. Save the Evopoint Biosciences Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs Evopoint Biosciences Inc.’s studies test, most open studies first — 4 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
5 of Evopoint Biosciences Inc.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- 1JJan ’27’27
- 1FFeb
- MMar
- AApr
- 1MMay
- JJun
- 1JJul
- AAug
- SSep
- OOct
- NNov
All 5
- Dec 2026Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsAnti-TF/TOP1i Antibody-drug Conjugate XNW28012 · NCT06799637
- Jan 2027To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaXNW5004 · NCT06702605
- Feb 2027A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard TreatmentNCT06987500
- May 2027Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic TherapyAnti-TF/TOP1i Antibody-drug Conjugate XNW28012 · Phase 3 · NCT07823049
- Jul 2027Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerXNW5004 · NCT06702995
Add all 5 to your calendar (.ics) → With an account.
All 21 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 19
- 20
- 421
- 22
- 23
- 24
- 25
- 426
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Evopoint Biosciences Inc..
- Evopoint Biosciences Inc.21 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 21 of 21.
- Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06702995Phase 1/2
- A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard TreatmentRecruitingNCT06987500Phase 1/2
- Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic TherapyRecruitingNCT07823049Phase 3
- Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell LymphomaRecruitingNCT07730515Phase 1/2
- Study of XNW5004 Tablets in Advanced Prostate CancerNot yet recruitingNCT07730580Phase 2
- Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic CancerNot yet recruitingNCT07707674Phase 1
- Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular LymphomaRecruitingNCT07545603Phase 2
- Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsRecruitingNCT06799637Phase 1/2
- A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT06776952Phase 3
- A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid TumorNot yet recruitingNCT07327294Phase 1/2
- To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaNot yet recruitingNCT06702605Phase 2
- Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)Not yet recruitingNCT05204368Phase 3
- To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced TumorsCompletedNCT06558513Phase 1/2
- Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)TerminatedNCT06022757Phase 1/2
- Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)CompletedNCT05204563Phase 3
- Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal FunctionCompletedNCT04787562Phase 1
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/CilastatinCompletedNCT04482569Phase 1
- Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy SubjectsCompletedNCT04802863Phase 1
- Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid TumorsCompletedNCT03901950Phase 1
- To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.CompletedNCT04801043Phase 1
- The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health SubjectCompletedNCT04040907Phase 1